Agustín Martínez Berriotxoa-rekin lankidetzan egindako argitalpenak (19)

2020

  1. Ankle-brachial index and arterial vascular events in systemic lupus erythematosus patients: A 5-year prospective cohort

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 978-984

  2. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

    PLoS ONE, Vol. 15, Núm. 9 September

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

2015

  1. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients

    Clinical and experimental rheumatology, Vol. 33, Núm. 2

2012

  1. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

    Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. Indicaciones de biopsias cutáneas, sinoviales y viscerales en las vasculitis

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 10, Núm. 31, pp. 2103-2106

  2. Indications of synovial, visceral and skin biopsies in vasculitis

    Medicine, Vol. 10, Núm. 31, pp. 2103-2106

  3. Predictors of major infections in systemic lupus erythematosus.

    Arthritis research & therapy, Vol. 11, Núm. 4

  4. Síndrome antifosfolipídico en el siglo xxi

    Medicina Clinica, Vol. 133, Núm. 10, pp. 390-396

2008

  1. Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences

    Rheumatology, Vol. 47, Núm. 6, pp. 920-923

2007

  1. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 6, pp. 815-817

  2. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus

    Lupus, Vol. 16, Núm. 10, pp. 810-816

2006

  1. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

    Lupus, Vol. 15, Núm. 9, pp. 577-583

  2. High risk of tuberculosis in systemic lupus erythematosus?

    Lupus, Vol. 15, Núm. 4, pp. 232-235

2004

  1. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus

    Lupus, Vol. 13, Núm. 12, pp. 900-905

  2. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus

    Lupus, Vol. 13, Núm. 12, pp. 927-933

  3. Vitamin Supplementation and Risk of Stroke [1] (multiple letters)

    Journal of the American Medical Association

2003

  1. Homocisteína plasmática en pacientes con lupus eritematoso sistémico

    Medicina Clinica, Vol. 120, Núm. 18, pp. 681-685